Item 5.02 Departure of Directors or Certain Officers; Election of Directors;

Appointment of Certain Officers; Compensatory Arrangements of Certain

Officers.

On September 21, 2022, LogicBio Therapeutics, Inc. (the "Company") entered into a consulting agreement (the "Consulting Agreement") with Cecilia Jones, Chief Financial Officer and Treasurer of the Company, effective as of September 23, 2022, pursuant to which Ms. Jones will provide financial consulting services for a base rate of $1 per day. Under the Consulting Agreement, Ms. Jones will be deemed to be under "Employment" (as defined in the LogicBio Therapeutics, Inc. 2018 Equity Incentive Plan (the "Plan")) with the Company from her initial date of employment through the date of termination of the Consulting Agreement, and all other terms of her stock options or other equity awards granted pursuant to the Plan will continue to apply. The Consulting Agreement has a term of three months and may be terminated by either party with 15 days' written notice.

The foregoing description of the Consulting Agreement is qualified in its entirety by reference to the full text of the Consulting Agreement which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference in this Item 5.02.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits.

Exhibit
  No.       Description

10.1          Consulting Agreement by and between Cecilia Jones and LogicBio
            Therapeutics, Inc., effective as of September 23, 2022

 104        Cover Page Interactive Data File (embedded within the Inline XBRL
            document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses